Where can I buy Myovant Sciences (myov)?
Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Myovant Sciences' stock price today?
What is Myovant Sciences'stock symbol?
Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV." Who are Myovant Sciences' major shareholders? Myovant Sciences' stock is owned by a number of institutional and retail investors.
Why did Myovant Sciences shares fall despite Q2 earnings beat?
Why Did Myovant Sciences Shares Fall Despite Q2 Earnings Beat? Tucked in its Q2 earnings release, Myovant Sciences Ltd (NYSE: MYOV) said that Pfizer Inc (NYSE: PFE) has notified its option decision for international rights to relugolix in oncology.
Where can I buy shares of myov?
Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is Myovant a public company?
and BASEL, Switzerland , May 30, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women's health and prostate cancer, today announced the pricing of its underwritten public offering of 15,151,516 of ...
Is Myovant a buy?
Myovant Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Should I buy MYOV stock?
The financial health and growth prospects of MYOV, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Is Myovant a good company?
Myovant is a great place to work. Small, Focused and growing with the right foundations. Small company with Solid Foundation to build upon in several areas.
Should I buy or sell Myovant Sciences stock right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 2 hold rat...
What is Myovant Sciences' stock price forecast for 2022?
3 Wall Street analysts have issued 12 month price targets for Myovant Sciences' shares. Their forecasts range from $12.00 to $20.00. On average, th...
How has Myovant Sciences' stock price performed in 2022?
Myovant Sciences' stock was trading at $15.57 at the start of the year. Since then, MYOV stock has decreased by 24.0% and is now trading at $11.83....
When is Myovant Sciences' next earnings date?
Myovant Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Myo...
How were Myovant Sciences' earnings last quarter?
Myovant Sciences Ltd. (NYSE:MYOV) posted its earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, topping...
Who are Myovant Sciences' key executives?
Myovant Sciences' management team includes the following people: Mr. David C. Marek , CEO & Director (Age 57, Pay $1.31M) ( LinkedIn Profile ) M...
Who are some of Myovant Sciences' key competitors?
Some companies that are related to Myovant Sciences include Apellis Pharmaceuticals (APLS) , Cerevel Therapeutics (CERE) , Galapagos (GLPG) , T...
What other stocks do shareholders of Myovant Sciences own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeuti...
When did Myovant Sciences IPO?
(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $...
About Myovant Sciences
Myovant Sciences (NYSE:MYOV) Frequently Asked Questions
Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women's health and endocrine diseases.
